Patents by Inventor Jonathan Thielman

Jonathan Thielman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-Inflammatory Compounds
    Publication number: 20260176288
    Abstract: The invention provides compounds of Formula (I), and pharmaceutically acceptable salts and pharmaceutical compositions thereof, which are useful as inhibitors of STAT family members, and methods for using such compounds to treat, ameliorate or prevent an inflammatory disease or allergic disease, including asthma and atopic dermatitis associated with STAT proteins, especially associated with IL-4 signaling.
    Type: Application
    Filed: December 16, 2025
    Publication date: June 25, 2026
    Inventors: Sourav GHORAI, Robert LEON, Sean RAFFERTY, Jonathan THIELMAN, William CASSELS, Samuel BARTLETT, Jiajun ZHANG, Peilin XU, Yuk Ming SIU, Scott A. MITCHELL, Yat Sun OR
  • Fused Heterobicyclic Antiviral Agents
    Publication number: 20250304542
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the cellular entry of hepatitis B virus (HBV) and/or hepatitis D virus (HDV) or interfere with the function of the life cycle of HBV and/or HDV and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV and/or HDV infection. The invention also relates to methods of treating an HBV and/or HDV infection in a subject by administering a therapeutically effective amount of a compound of the present invention.
    Type: Application
    Filed: March 10, 2025
    Publication date: October 2, 2025
    Inventors: Sean RAFFERTY, William CASSELS, Samuel BARTLETT, Nathaniel Thomas KENTON, Jonathan THIELMAN, Joseph D. PANARESE, Scott MITCHELL
  • Heterocyclic antiviral agents
    Patent number: 12145941
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 6, 2022
    Date of Patent: November 19, 2024
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Joseph D. Panarese, Sean Rafferty, Jonathan Thielman, Nathaniel T. Kenton, Samuel Bartlett, Yat Sun Or
  • Fused Heterobicyclic Antiviral Agents
    Publication number: 20240368096
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, which inhibit the cellular entry of hepatitis B virus (HBV) and/or hepatitis D virus (HDV) or interfere with the function of the life cycle of HBV and/or HDV and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV and/or HDV infection. The invention also relates to methods of treating an HBV and/or HDV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: February 21, 2024
    Publication date: November 7, 2024
    Inventors: Samuel BARTLETT, Joseph D. PANARESE, Sourav GHORAI, Nathaniel Thomas KENTON, Sean RAFFERTY, Jonathan THIELMAN, Peilin XU, Bin WANG, William CASSELS, Scott MITCHELL, Yat Sun OR
  • FUSED HETEROBICYCLIC ANTIVIRAL AGENTS
    Publication number: 20240140922
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the cellular entry of hepatitis B virus (HBV) and/or hepatitis D virus (HDV) or interfere with the function of the life cycle of HBV and/or HDV and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV and/or HDV infection. The invention also relates to methods of treating an HBV and/or HDV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: August 22, 2023
    Publication date: May 2, 2024
    Inventors: Samuel Bartlett, Joseph D. Panarese, Sourav Ghorai, Nathaniel Thomas Kenton, Sean Rafferty, Jonathan Thielman, Peilin Xu, Bin Wang, William Cassels, Scott Mitchell, Yat Sun Or
  • HETEROCYCLIC ANTIVIRAL AGENTS
    Publication number: 20230174542
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: December 6, 2022
    Publication date: June 8, 2023
    Inventors: Joseph D. Panarese, Sean Rafferty, Jonathan Thielman, Nathaniel T. Kenton, Samuel Bartlett, Yat Sun Or